RAF1 and neoplasm: Since the development of the first RAF monomer-selective inhibitor, vemurafenib, and its successful implementation for the treatment of metastatic BRAFV600E-melanoma, these inhibitors have been evaluated in other tumor types bearing the same mutation [29,60,61].